Cover Image
市場調查報告書

神經內分泌腫瘤:開發平台分析

Neuroendocrine Tumors - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 237878
出版日期 內容資訊 英文 304 Pages
訂單完成後即時交付
價格
Back to Top
神經內分泌腫瘤:開發平台分析 Neuroendocrine Tumors - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 304 Pages
簡介

神經內分泌腫瘤是在內分泌系統中產生荷爾蒙的細胞發現的腫瘤,具有高血糖、下痢、食欲減退/體重降低、身體部分肥胖或疙瘩、黃疸、頭痛、神經不安症、胃潰瘍等症狀。治療方法有手術、放射線治療、化療等。

本報告涵括全球神經內分泌腫瘤治療藥的開發中產品,提供您目前開發平台狀況和最新趨勢,後期階段及中止的計劃等資訊,還有主要企業及他們開發中的產品評估等。

簡介

  • 調查範圍

神經內分泌腫瘤概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

神經內分泌腫瘤:開發中的治療藥:各企業

神經內分泌腫瘤:開發中的治療藥:各大學·研究機關

神經內分泌腫瘤:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

神經內分泌腫瘤:開發中的產品:各企業

神經內分泌腫瘤:開發中的產品:各大學·研究機關

神經內分泌腫瘤:治療藥的開發企業

  • Advanced Accelerator Applications S.A.
  • Aegis Therapeutics, LLC
  • Amgen Inc.
  • AVEO Pharmaceuticals, Inc.
  • Boehringer Ingelheim GmbH
  • Chiasma, Inc.
  • Crinetics Pharmaceuticals, Inc.
  • 第一三共
  • Delcath Systems, Inc.
  • DexTech Medical AB
  • Eisai
  • Exelixis, Inc.
  • Foresee Pharmaceuticals, LLC
  • Hutchison MediPharma Limited
  • Intezyne, Inc
  • INVENT Pharmaceuticals, Inc.
  • Ipsen S.A.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Karyopharm Therapeutics, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Midatech Pharma Plc .
  • Millennium Pharmaceuticals, Inc.
  • MolMed S.p.A.
  • Northwest Biotherapeutics, Inc.
  • Novartis AG
  • OctreoPharm Sciences GmbH
  • OXiGENE, Inc.
  • Peptron, Inc.
  • Pfizer Inc.
  • Pharma Mar, S.A.
  • Progenics Pharmaceuticals, Inc.
  • Provectus Biopharmaceuticals, Inc.
  • Sompharmaceuticals S.A.
  • Strongbridge Biopharma plc
  • Vascular Biogenics Ltd.

神經內分泌腫瘤:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

神經內分泌腫瘤:最近的開發平台趨勢

神經內分泌腫瘤:暫停中的計劃

神經內分泌腫瘤:中止計劃

神經內分泌腫瘤:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8174IDB

Summary

Global Markets Direct's, 'Neuroendocrine Tumors - Pipeline Review, H1 2016', provides an overview of the Neuroendocrine Tumors pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors
  • The report reviews pipeline therapeutics for Neuroendocrine Tumors by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Neuroendocrine Tumors therapeutics and enlists all their major and minor projects
  • The report assesses Neuroendocrine Tumors therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Tumors
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumors pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Neuroendocrine Tumors Overview
  • Therapeutics Development
  • Neuroendocrine Tumors - Therapeutics under Development by Companies
  • Neuroendocrine Tumors - Therapeutics under Investigation by Universities/Institutes
  • Neuroendocrine Tumors - Pipeline Products Glance
  • Neuroendocrine Tumors - Products under Development by Companies
  • Neuroendocrine Tumors - Products under Investigation by Universities/Institutes
  • Neuroendocrine Tumors - Companies Involved in Therapeutics Development
  • Neuroendocrine Tumors - Therapeutics Assessment
  • Drug Profiles
  • Neuroendocrine Tumors - Recent Pipeline Updates
  • Neuroendocrine Tumors - Dormant Projects
  • Neuroendocrine Tumors - Discontinued Products
  • Neuroendocrine Tumors - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Neuroendocrine Tumors, H1 2016
  • Number of Products under Development for Neuroendocrine Tumors - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Neuroendocrine Tumors - Pipeline by Advanced Accelerator Applications S.A., H1 2016
  • Neuroendocrine Tumors - Pipeline by Aegis Therapeutics, LLC, H1 2016
  • Neuroendocrine Tumors - Pipeline by Amgen Inc., H1 2016
  • Neuroendocrine Tumors - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
  • Neuroendocrine Tumors - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Neuroendocrine Tumors - Pipeline by Chiasma, Inc., H1 2016
  • Neuroendocrine Tumors - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2016
  • Neuroendocrine Tumors - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Neuroendocrine Tumors - Pipeline by Delcath Systems, Inc., H1 2016
  • Neuroendocrine Tumors - Pipeline by DexTech Medical AB, H1 2016
  • Neuroendocrine Tumors - Pipeline by Eisai Co., Ltd., H1 2016
  • Neuroendocrine Tumors - Pipeline by Exelixis, Inc., H1 2016
  • Neuroendocrine Tumors - Pipeline by Foresee Pharmaceuticals, LLC, H1 2016
  • Neuroendocrine Tumors - Pipeline by Hutchison MediPharma Limited, H1 2016
  • Neuroendocrine Tumors - Pipeline by Intezyne, Inc, H1 2016
  • Neuroendocrine Tumors - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016
  • Neuroendocrine Tumors - Pipeline by Ipsen S.A., H1 2016
  • Neuroendocrine Tumors - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016
  • Neuroendocrine Tumors - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Neuroendocrine Tumors - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2016
  • Neuroendocrine Tumors - Pipeline by Midatech Pharma Plc, H1 2016
  • Neuroendocrine Tumors - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Neuroendocrine Tumors - Pipeline by MolMed S.p.A., H1 2016
  • Neuroendocrine Tumors - Pipeline by Northwest Biotherapeutics, Inc., H1 2016
  • Neuroendocrine Tumors - Pipeline by Novartis AG, H1 2016
  • Neuroendocrine Tumors - Pipeline by OctreoPharm Sciences GmbH, H1 2016
  • Neuroendocrine Tumors - Pipeline by OXiGENE, Inc., H1 2016
  • Neuroendocrine Tumors - Pipeline by Peptron, Inc., H1 2016
  • Neuroendocrine Tumors - Pipeline by Pfizer Inc., H1 2016
  • Neuroendocrine Tumors - Pipeline by Pharma Mar, S.A., H1 2016
  • Neuroendocrine Tumors - Pipeline by Progenics Pharmaceuticals, Inc., H1 2016
  • Neuroendocrine Tumors - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016
  • Neuroendocrine Tumors - Pipeline by Sompharmaceuticals S.A., H1 2016
  • Neuroendocrine Tumors - Pipeline by Strongbridge Biopharma plc , H1 2016
  • Neuroendocrine Tumors - Pipeline by Vascular Biogenics Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Neuroendocrine Tumors Therapeutics - Recent Pipeline Updates, H1 2016
  • Neuroendocrine Tumors - Dormant Projects, H1 2016
  • Neuroendocrine Tumors - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Neuroendocrine Tumors, H1 2016
  • Number of Products under Development for Neuroendocrine Tumors - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top